16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study

Abstract

Lebrikizumab (LEB) is a novel, high affinity monoclonal antibody targeting interleukin (IL) 13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor complex and subsequent signaling. Adults (EASI ≥16, IGA ≥3, and chronic AD for ≥1 year) were randomized 3:3:3:2 to subcutaneous LEB 125 mg q4w (250 mg loading dose [LD]; n = 73); 250 mg q4w (500 mg LD; n = 80), 250 mg q2w (500 mg LD at week [wk] 0 and 2; n = 75), or placebo (n = 52) for 16 weeks. Outcomes included percent change from Baseline (cfB) in EASI to wk 16 (primary) and EASI50, EASI75, EASI90, IGA 0/1 and pruritus NRS change ≥4 points at wk 16 (secondary end points).